IOVA
IOVA clinical trials: IOVANCE BIOTHERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where IOVANCE BIOTHERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 37
- Trials linked
- 16
- As lead sponsor
- 21
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IOVA on the catalyst calendar · IOVA registry changes
- Primary completion Jun 19, 2026ActualPhase 1NCT06566092Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsIovance Biotherapeutics, Inc. · Soft Tissue SarcomaTerminatedIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2033Sponsor estimatePhase 2NCT07741877A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaIovance Biotherapeutics, Inc. · SarcomaRecruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT07288203A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaIovance Biotherapeutics, Inc. · Melanoma (Skin Cancer)Active, not recruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2028Sponsor estimatePhase 3NCT05727904Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced...Iovance Biotherapeutics, Inc. · Metastatic MelanomaRecruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2034Sponsor estimatePhase 1/Phase 2NCT07743723A Study of IOV-5001 in Adults With Advanced Solid TumorsIovance Biotherapeutics, Inc. · Advanced Solid TumorsNot yet recruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2025ActualPhase 2NCT03108495Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaIovance Biotherapeutics, Inc. · Cervical CarcinomaTerminatedIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimatePhase 2NCT04614103Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerIovance Biotherapeutics, Inc. · Metastatic Non Small Cell Lung CancerRecruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2032Sponsor estimatePhase 1/Phase 2NCT06940739A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelIovance Biotherapeutics, Inc. · Unresectable MelanomaRecruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1/Phase 2NCT05361174A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma...Iovance Biotherapeutics, Inc. · Unresectable MelanomaRecruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2026ActualPhase 2NCT03645928Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsIovance Biotherapeutics, Inc. · Metastatic MelanomaTerminatedIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05398640Expanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseIovance Biotherapeutics, Inc. · Unresectable MelanomaAvailableIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2024ActualPhase 2NCT02360579Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaIovance Biotherapeutics, Inc. · Metastatic MelanomaCompletedIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2024ActualPhase 1NCT04155710Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLIovance Biotherapeutics, Inc. · Chronic Lymphocytic LeukemiaCompletedIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 2NCT06481592A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.Iovance Biotherapeutics, Inc. · Endometrial CancerRecruitingIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 8, 2022ActualPhase 2NCT03083873Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckIovance Biotherapeutics, Inc. · Squamous Cell Carcinoma of the Head and NeckCompletedIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2021Sponsor estimatePhase 2NCT03419559Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerIovance Biotherapeutics, Inc. · Non Small Cell Lung CancerWithdrawnIOVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2017ActualPhase 1NCT01937468Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-DiseaseDana-Farber Cancer Institute · Chronic Graft Versus Host DiseaseActive, not recruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2027Sponsor estimatePhase 2NCT03449108LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic...M.D. Anderson Cancer Center · Bone SarcomaActive, not recruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2029Sponsor estimatePhase 2NCT07925333Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerBeth Israel Deaconess Medical Center · Kidney CancersNot yet recruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT05686226E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersChristian Hinrichs · Cervical CancerRecruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2028Sponsor estimatePhase 1/Phase 2NCT05639972E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersChristian Hinrichs · HPV-Associated Cervical CarcinomaRecruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2028Sponsor estimatePhase 1NCT05483491KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerChristian Hinrichs · Gastric CancerRecruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2027Sponsor estimatePhase 1NCT05607095A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma...Memorial Sloan Kettering Cancer Center · Uveal MelanomaRecruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 1NCT05640193A Study of LN-144 in People With Metastatic Melanoma to the BrainMemorial Sloan Kettering Cancer Center · Metastatic MelanomaActive, not recruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2033Sponsor estimatePhase 1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD · Malignant Pleural EffusionRecruitingIOVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 12 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner